Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study

Aliment Pharmacol Ther 2010; 32: 1102–1112 Summary Background  Velusetrag is an orally active 5‐HT4 receptor agonist of potential benefit in treating chronic idiopathic constipation. Aim  To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic constipation. Methods  Aft...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2010-11, Vol.32 (9), p.1102-1112
Hauptverfasser: Goldberg, M., Li, Y.‐P., Johanson, J. F., Mangel, A. W., Kitt, M., Beattie, D. T., Kersey, K., Daniels, O.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Azabicyclo Compounds - therapeutic use
Biological and medical sciences
Chronic Disease
Clinical trials
Constipation
Constipation - drug therapy
Defecation - drug effects
Diarrhea
Digestive system
Dose-Response Relationship, Drug
Double-Blind Method
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Agents - therapeutic use
Headache
Humans
Intestine
Male
Medical sciences
Middle Aged
Nausea
Other diseases. Semiology
Pharmacology. Drug treatments
Serotonin 5-HT4 Receptor Agonists - therapeutic use
Serotonin S4 receptors
Statistical analysis
Statistics as Topic
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Treatment Outcome
Vomiting
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aliment Pharmacol Ther 2010; 32: 1102–1112 Summary Background  Velusetrag is an orally active 5‐HT4 receptor agonist of potential benefit in treating chronic idiopathic constipation. Aim  To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic constipation. Methods  After a 2‐week baseline period, patients [
ISSN:0269-2813
1365-2036
DOI:10.1111/j.1365-2036.2010.04456.x